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Abstract
Genital Chlamydia trachomatis (Ct) infection induces protective immunity that depends on 
interferon-γ producing CD4 T-cells. By contrast, mucosal exposure to ultraviolet light (UV)-
inactivated Ct (UV-Ct) generated regulatory T-cells that exacerbated subsequent Ct infection. We 
show that mucosal immunization with UV-Ct complexed with charge-switching synthetic 
adjuvant particles (cSAP) elicited long-lived protection in conventional and humanized mice. UV-
Ct-cSAP targeted immunogenic uterine CD11b+CD103− dendritic cells (DCs), whereas UV-Ct 
accumulated in tolerogenic CD11b−CD103+ DCs. Regardless of vaccination route, UV-Ct-cSAP 
induced systemic memory T-cells, but only mucosal vaccination induced effector T-cells that 
rapidly seeded uterine mucosa with resident memory T-cells (TRM). Optimal Ct clearance required 
both TRM seeding and subsequent infection-induced recruitment of circulating memory T-cells. 
*
 Correspondence to: Ulrich H. von Andrian, M.D.: uva@hms.harvard.edu or Georg Stary, M.D.: georg_stary@hms.harvard.edu. 
One Sentence Summary:
Mucosal vaccination with inactivated C. trachomatis linked to adjuvant nanocarriers elicits two memory T cell subsets that protect 
against uterine C. trachomatis infection.
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Thus, UV-Ct-cSAP vaccination generated two synergistic memory T-cell subsets with distinct 
migratory properties.
Graphical Abstract
Protection against C. trachomatis infection after mucosal UV-Ct–cSAP vaccination. Upon 
mucosal vaccination, dendritic cells carry UV-Ct–cSAP to lymph nodes and stimulate CD4 T 
cells. Effector T cells are imprinted to traffic to uterine mucosa (1st wave) and establish tissue-
resident memory cells (TRM). Vaccination also generates circulating memory T cells. Upon genital 
Ct infection, local reactivation of uterine TRM triggers the recruitment of the circulating memory 
subset (2nd wave). Optimal pathogen clearance requires both waves of memory cells.
INTRODUCTION
Although subcutaneous (s.c.) or intramuscluar (i.m.) vaccination can generate efficient 
systemic and cutaneous immunity against many pathogens, vaccination by these non-
mucosal routes often induces little or no protection at mucosal surfaces (1). A reason for this 
shortcoming is thought to be the differential imprinting of activated effector/memory 
lymphocytes in regional lymphoid tissues. These organs are populated by specialized 
antigen (Ag) presenting dendritic cells (DCs) that induce the expression of tissue-specific 
homing receptors in T and B cells (2-4). Acquisition of tissue tropism enables the 
preferential migration of Ag-experienced lymphocytes to regions of the body that are 
associated with the secondary lymphoid organs where Ag was first encountered (2, 3, 5-11). 
Thus, while intra- or subcutaneous and i.m. vaccines act in peripheral lymph nodes (LNs) to 
induce primarily skin-homing memory cells, mucosal vaccine exposure targets Ags into 
mucosa-associated lymphoid tissues (MALT) and focuses the ensuing memory response 
toward mucosal surfaces (6, 12-16). However, only a handful of mucosal vaccines are 
currently available for use in humans, and most of these vaccines consist of replicating 
microorganisms, which may themselves cause infections in vulnerable individuals (17). 
Such safety concerns could be avoided with non-replicating vaccines, such as killed 
pathogens or inanimate Ags, however, mucosal exposure to non-infectious Ags is typically 
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insufficient to elicit a protective immune response unless the Ags are combined with potent 
adjuvants that are often too toxic for use in humans (18, 19).
These immunobiological challenges present formidable obstacles to the development of 
effective vaccines for many mucosal pathogens. One prominent example among these 
'intractable' pathogens is Chlamydia trachomatis (Ct), a gram-negative obligatory 
intracellular bacterium that infects mucosal epithelial cells. Ct is the most common sexually 
transmitted bacterial pathogen and the leading cause of female infertility, ectopic pregnancy 
(20-22) and infectious blindness worldwide (23). Clinical trials in the 1960's with 
inactivated elementary bodies (EBs), the infectious form of Ct (24), achieved partial early 
protection, but at later stages some vaccinated individuals experienced more severe 
symptoms upon ocular Ct exposure than placebo recipients (24-30). The underlying 
mechanism for this apparently enhanced risk of Ct-induced pathology following exposure to 
killed Ct is not understood. To this day, this persistent uncertainty has stymied further 
clinical development of Ct vaccines.
RESULTS & DISCUSSION
Effect of uterine mucosal exposure to live and killed Ct
Here, we have used mice to explore the immunological consequences of mucosal exposure 
to live or killed Ct by performing intra-uterine (i.u.) inoculations of either infectious Ct 
(serovar L2 unless stated otherwise) or ultraviolet light-inactivated Ct (UV-Ct). The animals 
were re-challenged with live Ct four weeks later and uterine bacterial burden was assessed 
after 6 days (Fig. 1A). Consistent with earlier observations in this model (31), mice that had 
been previously infected with Ct acquired protective immunity as evidenced by a ~50-fold 
reduction in bacterial burden upon reinfection as compared to naive controls (Fig. 1B). In 
contrast, the bacterial burden in infected mice that had been previously exposed to UV-Ct 
was 5- to 10-fold greater than in the non-immunized group. This exacerbated susceptibility 
to infection in the UV-Ct group was intriguingly reminiscent of the reported outcome of 
human vaccine trials five decades ago (25-29) and suggested that inactivated Ct was not 
merely ‘invisible’ to the host immune system, but somehow promoted tolerance.
Having thus determined that mucosal exposure to UV-Ct induces a pronounced tolerogenic 
immune response in mice, we asked whether mixing UV-Ct with an adjuvant could convert 
UV-Ct into an immunogen that might elicit protective immunity. However, i.u. injection of 
UV-Ct mixed with alum or with two different TLR agonists, imiquimod (TLR7 ligand) or 
CpG (TLR9 ligand), not only failed to confer protection, but also rendered mice more 
susceptible to reinfection, similar to UV-Ct alone (Fig. 1C). Interestingly, when mice were 
instead immunized by s.c. injection, UV-Ct provoked neither a tolerogenic response nor did 
it confer measurable protection, even when combined with adjuvants. Thus, the route of 
immunization can determine not only the tissue-tropism of effector/memory cells, but 
apparently also the tolerogenicity of a given Ag.
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Conjugation of UV-inactivated Ct to charge-switching synthetic adjuvant particles
In light of these observations, we speculated that the lack of immunogenicity of i.u. 
exposure to crude mixtures of adjuvants with UV-Ct may have been due to differential 
permeability of the intact mucosal barrier to UV-Ct and/or free adjuvants. Thus, we 
reasoned that physical linkage of an adjuvant to UV-Ct may be necessary to allow both 
vaccine components to cross the epithelial barrier and be acquired by the same submucosal 
immunogenic DCs. To test this idea, we engineered modified charge-switching synthetic 
particles (cSPs), biodegradable nanocarriers that were developed recently to target 
encapsulated antibiotics to bacterial surfaces (32). Using an emulsion-based manufacturing 
process, cSPs self-assemble from a tri-block co-polymer, poly(D,L-lactic-co-glycolic acid)-
b-poly(L-histidine)-bpoly(ethylene glycol) (PLGA-PLH-PEG) to form a hydrophobic core 
(PLGA) and a bilayered hydrophilic surface consisting of an inner layer of PLH and an outer 
layer of PEG (32). At physiologic pH7.4 cSPs carry a slight negative surface charge, but 
acidification to below pH6.5 induces protonation of PLH imidazole groups, rendering cSPs 
cationic and allowing them to form conjugates with negatively charged bacteria (32). For 
use in vaccines, we modified cSPs by incorporating a second hydrophobic polymer, 
poly(D,L-lactic acid), that was covalently coupled to R848 (a.k.a. resiquimod), a potent 
TLR7/8 agonist (PLA-R848). Recent work has shown that following s.c. injection into mice 
PEGylated PLA-R848 containing nanoparticles are phagocytosed by DCs and release free 
R848 within endosomes resulting in efficient activation of endosomal TLR7 and DC 
maturation, while minimizing systemic exposure to this adjuvant (33). Thus, by 
incorporating R848 into cSPs, we created charge-switching synthetic adjuvant particles 
(cSAPs) that were then mixed with UV-Ct EBs in aqueous buffer (Fig. 1D). Following 
acidification, cSAPs formed conjugates with UV-Ct, as confirmed by flow cytometry (Figs. 
1E, F), transmission electron microscopy (Fig. 1G) and dynamic light scattering analysis 
(Fig. 1H). By contrast, synthetic adjuvant particles (SAPs) that lacked PLH and could not 
undergo surface-charge switching failed to bind UV-Ct and were used as a control.
Effect of uterine mucosal vaccination with UV-Ct-cSAP conjugates
Having verified that cSAPs serve as an effective tool to attach a potent small molecule 
adjuvant, R848, to UV-Ct we compared the effect of i.u. exposure to UV-Ct alone or UV-Ct 
mixed with free SAPs (UV-Ct + SAP) or conjugated with either cSAPs (UV-Ct–cSAP) or 
adjuvant-free cSPs (UV-Ct– cSP) using the same i.u. prime/challenge protocol as above. 
Again, pre-conditioning with UV-Ct rendered mice hypersusceptible to subsequent Ct 
challenge, and this tolerogenic effect was preserved in animals that had received UV-Ct + 
SAP or UV-Ct–cSPs (Fig. 2A). By contrast, bacterial clearance was dramatically 
accelerated in mice that had been immunized with UV-Ct–cSAP (Fig. 2B). Remarkably, the 
extent of vaccine-induced protection was equivalent, if not superior, when compared to 
animals with ‘natural’ memory after previous Ct infection. These results were independently 
confirmed when uteri of challenged mice were analyzed by blinded observers for the 
presence of infectious Ct by in vitro testing of tissue extracts for inclusion-forming units in 
McCoy cells (Figs. 2C, S1). Robust protection was also achieved when cSAPs were 
conjugated to formalin-inactivated Ct (not shown) or to another UV-inactivated strain of Ct, 
serotype E (Ct-E) (Fig. S2), or to C. muridarum (Cm), a mouse adapted strain (Fig. 2D).
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Of note, while pathological changes in murine uteri infected with human adapted strains of 
Ct are variable, infection of naive mice with Cm caused reproducible tissue damage 
resulting in accumulation of serous exudate in fallopian tubes (hydrosalpinx), reminiscent of 
the pathology induced by chronic Ct infection in humans. By contrast, animals that had 
received i.u. UV-Cm-cSAP vaccination were profoundly protected against hydrosalpinx 
formation when compared to naive animals or recipients of UV-Cm alone (Fig. 2E).
Importantly, the differential effects of i.u. conditioning with UV-Ct–cSAP and UV-Ct 
persisted unabated for at least 6 months; the former continued to afford profound protection, 
while the latter predisposed to enhanced susceptibility to Ct rechallenge, indicating that 
mucosal exposure to UV-Ct in both immunogenic and tolerogenic contexts elicits sustained 
and qualitatively unchanging memory (Fig. 2F).
UV-Ct-cSAP vaccination induces Ct specific protective T-helper 1 memory cells
In light of the fact that the charge-based conjugation of cSAPs to UV-Ct was apparently 
sufficient not only to permanently avert the default tolerance response to UV-Ct, but also to 
produce robust long-term protective immunity that prevented infection-induced tissue 
damage, we set out to dissect the underlying immunological mechanisms. Recent clinical 
evidence suggests that humans develop at least partially protective immunity upon clearance 
of genital Ct infection, whereby interferon (IFN)-γ production, presumably by T-helper 1 
(TH1) cells, was inversely correlated with the risk for reinfection (34-36). Although 
mechanistic information in humans is sparse and far from definitive, the available data are 
consistent with experiments in mice where bacterial clearance after genital Ct or Cm 
infection is known to require TH1 cells (31, 37, 38). Mouse experiments have also shown 
that during Ct or Cm infection, naive T cells (TN) differentiate into effector T cells (TEff) in 
uterus-draining lymph nodes (LNs), and these TEff are then recruited to the genital mucosa 
to mediate bacterial clearance (39-41). TH1 cells are also a key component of long-term 
protective memory post infection, although a role for B cells and antibodies has also been 
reported (42-47).
Our analysis of UV-Ct–cSAP immunized mice revealed a robust Ct-specific antibody 
response that was equivalent to that elicited by Ct infection and ~twice as high as in UV-Ct 
exposed mice (Fig. S3A). Moreover, i.u. immunization with UV-Ct–cSAP increased uterine 
mucosa-resident CD8 T cells (Fig. S3B) as well as CD4 T cells (see below). To ask which 
component(s) of this multi-facetted response to UV-Ct–cSAP was required for mucosal 
protection we measured bacterial burdens after genital Ct infection in vaccinated mutant 
mice that lacked either B cells (μMt mice, which contain a deletion of the IgM heavy chain) 
or CD8 T cells (Cd8−/− mice) or CD4 T cells (B6.129S2-H2dlAb1-Ea/J (referred to as MHC-
II−/−) mice (48)) or both B and T cells (Rag2−/− mice). Neither the absence of B cells nor 
CD8 T cells had a detectable impact on bacterial levels, whereas Rag2−/− mice (Fig. S4) 
and MHC-II−/− mice were completely unprotected against Ct challenge (Fig. 3A). Of note, 
unlike wildtype animals, mice that were devoid of CD4 T cells did not suffer increased 
bacterial burdens after UV-Ct conditioning, indicating that CD4+ T cells are not only needed 
for pathogen clearance but also for UV-Ct induced tolerance.
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Since the above experiments demonstrated that CD4 T cells are required for the sequelae of 
both UV-Ct and UV-Ct–cSAP exposure, we asked whether CD4 T cells alone were 
sufficient to confer these effects. Thus, we adoptively transferred purified leukocyte subsets 
from immunized mice to naïve recipients that were subsequently challenged with Ct. Partial 
protection against genital Ct challenge was achieved after transferring 1×107 splenic CD4 T 
cells from mice that had received i.u. injections of either Ct or UV-Ct–cSAP, whereas 
transfer of CD8 T cells or T cell depleted splenocytes had no effect (Fig. 3B). Transfer of 
CD4 T cells from UV-Ct conditioned donors conferred enhanced susceptibility to infection.
Having determined that CD4 memory T cells are both necessary and sufficient for Ct-
specific protective memory, as well as tolerance, following immunization with UV-Ct-cSAP 
and UV-Ct, respectively, we asked how Ct-specific CD4 TN respond to either stimulus, as 
compared to Ct infection. To this end, TN from CD90.1+ transgenic NR1 mice (40), in 
which most CD4 T cells express a Ct specific TCR (Figs. S5), were adoptively transferred 
into groups of congenic (CD90.2+) hosts that were subsequently immunized i.u. with Ct, 
UV-Ct or UV-Ct–cSAP. Four days later, NR1 cells had responded identically to Ct infection 
and UV-Ct–cSAP immunization; they had vigorously proliferated and expanded in the 
draining LN (Figs. 3C, D) and they also accumulated in the uterine mucosa (Fig. 3E). 
Moreover, upon in vitro rechallenge with UV-Ct pulsed autologous DCs, the vast majority 
of uterine and LN-resident NR1 cells in both groups produced one or more effector 
cytokines, including IFN-γ, interleukin (IL)-2, and tumor necrosis factor (TNF)-α (Fig. 3F). 
By contrast, in UV-Ct exposed animals, NR1 cells showed less proliferation and 
accumulation in LNs and uterus and they secreted little or no cytokines, similar to TN.
Mucosal exposure UV-Ct generates Ct specific regulatory T cells
Although the encounter of UV-Ct evoked a blunted TEff response by Ct-specific CD4 T 
cells, this effect alone cannot explain why UV-Ct enhanced host susceptibility to subsequent 
Ct infection. The apparent tolerogenicity of UV-Ct clearly depended on CD4 T cells, since 
UV-Ct did not tolerize MHC-II−/− mice (Fig. 3A), while adoptive transfer of CD4 T cells 
from UV-Ct conditioned wildtype mice conferred tolerance to naive recipients (Fig. 3B). 
Thus, we hypothesized that mucosal UV-Ct exposure may not only compromise TEff 
differentiation of Ct-specific TN, but also instigate an alternative “career decision”, driving 
CD4 TN to differentiate into FoxP3+CD25+ regulatory T cells (Treg). To test this idea, we 
adoptively transferred to naïve hosts TN from NR1xFoxP3-eGFP donors after sorting the 
enhanced green fluorescent protein (eGFP) negative fraction (i.e. non-Treg). Recipients 
were then immunized with live Ct, UV-Ct or UV-Ct–cSAP. Indeed, there was a massive 
increase in FoxP3-eGFP+CD25+ NR1 cells in the draining LNs (Figs. 4A, B) and uterus 
(Figs. 4C, D) of UV-Ct exposed mice, while very few NR1 cells assumed a Treg phenotype 
in response to Ct infection or UV-Ct–cSAP vaccination. Since a priori eGFP+ Treg had 
been removed prior to TN transfer, the appearance of eGFP+ Treg after UV-Ct exposure was 
due to conversion of conventional TN, rather than expansion of existing Treg. These newly 
induced Tregs were required for tolerance to Ct infection, because anti-CD25 mediated Treg 
depletion in UV-Ct treated mice reduced uterine Ct burden upon subsequent infection to 
levels comparable to naive mice (Fig. 4E). Moreover, UV-Ct conditioned Il10−/− mice did 
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not suffer enhanced bacterial burdens upon i.u. Ct challenge (Fig. 4F), suggesting that the de 
novo induced Ct-specific Treg exerted their tolerogenic activity through the IL-10 pathway.
Differential mucosal antigen uptake and presentation by uterine dendritic cell subsets
What mechanisms are responsible for the differential T cell response to Ct or UV-Ct–cSAP 
versus UV-Ct? To address this question, we examined the phenotype and function of the 
three predominant uterus-resident MHC-II+ leukocyte populations (Fig. S6A): 
F4/80+CD11b+ macrophages that were CD11c–/low, CD103− and expressed variable levels 
of CX3CR1 and two equally sized subsets of CD11c+F4/80− DCs. One DC subset was 
CD103+ and expressed neither CD11b nor CX3CR1, while the second DC population was 
CD103−CD11b+CX3CR1+ (Fig. S6B). All three populations were negative for CD207/
Langerin and CD301b. Each of these candidate Ag presenting cells (APCs) were sorted 
from single-cell suspensions of uteri or draining LNs of naive and challenged mice and 
tested for Ct content and ability to stimulate NR1 TN in vitro and in vivo (Fig. 5A). At 18h 
after i.u. exposure to Ct, UV-Ct or UV-Ct–cSAP, uterine APCs had not changed 
significantly in total number or composition (Figs. S6C, S6D), and the amount of Ct-derived 
genetic material (determined by qPCR) acquired by both macrophages and CD326+ mucosal 
epithelial cells was similar in each group (Fig. 5B). By contrast, marked differences were 
apparent among the two DC subsets: live Ct and UV-Ct–cSAP were primarily acquired by 
CD103− DCs, whereas UV-Ct accumulated preferentially in CD103+ DCs. Similarly, at 24h 
after challenge, when sorted APCs were isolated from uterus-draining LNs, bacterial loads 
were exclusively detected in CD103− DCs after genital exposure to Ct and UV-Ct–cSAP, 
but not UV-Ct (Fig. 5C).
Consistent with the differential acquisition of Ct-derived genetic material, 3-day co-cultures 
of purified uterine APC subsets with NR1 TN revealed that CD103− DCs were singularly 
efficient at inducing T cell proliferation when they had been isolated from animals exposed 
to either Ct or UV-Ct–cSAP. By contrast, among UV-Ct exposed APCs only the CD103+ 
DCs promoted substantial proliferation of NR1 T cells, whereas macrophages failed to 
induce T cell proliferation regardless of the immunization regimen (Fig. 5D). This 
differential APC activity was recapitulated when APC subsets were isolated from vaccinated 
animals and injected into footpads of naive mice that had previously received NR1 TN; 
CD103− DCs, but not CD103+ DCs or macrophages, from Ct infected and UV-CtcSAP 
immunized mice stimulated NR1 TN proliferation in the recipients’ draining LNs (Fig. 5E). 
Footpad injection of sorted CD103+ DCs did not promote a significant in vivo response by 
NR1 cells in this experimental setting, however, when CD103+ DCs were isolated from UV-
Ct conditioned donors and exposed in vitro to NR1 TN, they uniquely promoted the 
appearance of FoxP3+CD25+ Treg (Fig. 5F).
In line with these functional observations, 18h after Ct infection or UV-Ct-cSAP 
immunization, uterine CD103− DCs preferentially upregulated immunostimulatory 
molecules, including CD80, CD86 and IL-12 (Figs. 5G, S6E). In contrast, upon 
immunization with UV-Ct, CD103+ DCs selectively upregulated certain anti-inflammatory 
pathways, including PD-L2 and IL-10. However, other markers of tolerogenic APCs 
Stary et al. Page 7
Science. Author manuscript; available in PMC 2015 December 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
remained either unchanged or were undetectable on uterine CD103+ DCs, such as PD-L1 
and RALDH, respectively.
We conclude that following mucosal exposure to live Ct and UV-Ct–cSAP, antigenic 
material is preferentially acquired and transported to the draining LNs by local immuno-
stimulatory CD103− DCs, whereas exposure to UV-Ct results in Ag acquisition by a 
tolerogenic DC subset that expresses CD103, leading to the induction of Tregs that then shift 
the balance from protection to long-lived tolerance in the genital mucosa. Of note, a similar 
division of labor between CD103+ and CD103− DCs has been described for the induction of 
intestinal tolerance and immunity, respectively (49). The differential Ag uptake by intestinal 
DC subsets is regulated by other mucosa-resident cell types (50-52), however, the 
mechanism(s) that regulate(s) differential Ag acquisition by uterine DCs remain(s) to be 
identified.
The route of administration determines UV-Ct–cSAP vaccine efficacy
Having established that targeting of uterine CD103− DCs by transcervical application of 
UV-Ct–cSAP generates long-term protection against genital Ct infection, we asked whether 
other routes of immunization could recapitulate this effect. Thus, mice were immunized with 
UV-Ct–cSAP either s.c. or i.n. and then challenged by i.u. Ct infection. Consistent with our 
experiments using mixtures of UV-Ct with conventional adjuvants (Fig. 1C), s.c. 
immunization with live Ct or UV-Ct–cSAP failed to protect (Fig. 6A). By contrast, exposure 
of nasopharyngeal mucosa to live Ct or UV-Ct–cSAP rendered mice resistant to genital Ct 
infection akin to i.u. immunization, and this cross-mucosal protective effect persisted 
unabated for at least 6 months (Fig. S7). Interestingly, unlike i.u. conditioning with UV-Ct, 
neither i.n. nor s.c. exposure to UV-Ct enhanced the animals’ susceptibility to genital Ct 
challenge, suggesting that the rules that govern regional immunity versus tolerance in the 
uterus may be distinct.
Rapid seeding of uterine mucosa with resident memory T cells (TRM) after mucosal but not 
subcutaneous UV-Ct–cSAP vaccination
The fact that percutaneous immunization was ineffective, while vaccination via two distant 
mucosal routes generated potent protection against genital Ct infection, implied that 
protective CD4 T cells required priming in a MALT environment for efficient mucosal 
targeting (12). To further investigate this idea, we adoptively transferred 1×104 NR1 TN into 
mice that were then immunized via different routes with UV-Ct–cSAP. Regardless of 
immunization route, the burst size of NR1 TEff in peripheral blood was equivalent in 
magnitude and peaked on day 5 (Fig. 6B). Similarly, 7 days and 30 days after i.n., s.c. or i.u. 
vaccination NR1 cells were equally represented in blood, spleen, LNs and liver, indicating 
that the route of immunization did not affect the differentiation or trafficking of TEff and 
memory cells to these non-mucosal sites (Fig. 6C). By contrast, i.u. and i.n. immunization 
generated Ag-experienced NR1 cells in the lung and uterus, while s.c. vaccination failed to 
generate mucosa-resident TEff (Fig. S8A-C). A closer examination of the kinetics of uterine 
TEff recruitment showed that NR1 TEff numbers increased gradually after i.n. vaccination, 
reaching a plateau on day 7. By contrast, i.u. vaccination resulted in a larger peak of uterus-
resident NR1 cells on day 7 followed by contraction of the resident T cell pool over the next 
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several day (Fig. 6D). By day 9, both mucosal vaccination strategies had elicited roughly 
similar uterus-resident T cell numbers, whereas NR1 cells remained essentially undetectable 
in uteri of s.c. immunized mice.
A critical protective role for uterine TRM upon transcervical Ct challenge
The above results suggested that two distinct pools of Ct-specific memory T cells were 
induced: One population was modest in size and consisted of mucosa-resident memory cells 
(TRM) that arose from TEff that accessed the uterus early after mucosal (but not s.c.) 
priming. The pronounced spike in early NR1 TEff accumulation that was seen after i.u. (but 
not i.n.) vaccination was presumably a consequence of local tissue irritation that spurred 
inflammatory recruitment signals in the uterus. It is unlikely that i.n. vaccination altered the 
steady-state milieu in the uterus, so the fact that uterine TEff numbers increased steadily 
during the first seven days post i.n. vaccination suggests the presence of constitutive 
mucosal recruitment signals for circulating TEff. While the nature of these steady-state 
signals remains to be elucidated, our results indicate that TEff were selectively ‘imprinted’ 
by mucosal (i.e. uterine or nasopharyngeal) APCs to engage this uterine recruitment 
pathway, whereas TEff generated in skin-draining LNs apparently lacked the prerequisite 
traffic molecule(s) for uterine homing. Moreover, the longevity of protection after i.n. 
vaccination (Fig. S7) indicates that TEff that accessed the uterus gave rise to TRM that 
persisted for at least six months without requiring the presence of local Ag.
The second vaccine-induced memory cell population was much larger than the uterus-
resident TRM and resided in blood and lymphoid tissues where these cells are thought to 
survey the body for recall Ag (53). Although systemic memory cells were elicited by all 
immunization routes, their protective capacity may vary due to differential imprinting of 
mucosal homing pathways during the priming phase (2-4, 54, 55). For example, recent work 
has shown that protective CD4 T cells require the α4β1 integrin to access uterine mucosa 
(56). We made use of this fact to assess the relative contribution by each memory pool to the 
clearance of a recurrent Ct infection (Fig. 6E). To this end, we adoptively transferred NR1 
TN into three groups of mice that then received i.n. UV-Ct–cSAP vaccination. Three days 
later, when activated NR1 TEff first appeared in the blood, animals in group 1 were given rat 
IgG every 48h and served as controls in which memory cells had continuous access to the 
uterus; group 2 received injections of a blocking anti-α4 integrin MAb every 48h, thus 
preventing uterine T cell homing throughout the experiment; group 3 received control IgG 
from day 3 to 7, allowing the first wave of Ct-specific TEff to seed the uterine mucosa. On 
day 9, when i.n. vaccinated control mice had established a stable uterine TRM pool (Fig. 
6D), all groups were either challenged by i.u. inoculation of Ct or left unchallenged, and 
group 3 was then switched to treatment with anti-α4 integrin MAb to prevent the secondary 
recruitment of circulating memory cells to the uterus. Animals were sacrificed on day 13 
after immunization to assess uterine bacterial burden and/or NR1 cell distribution.
As expected (56), α4 integrin blockade in groups 2 and 3 profoundly affected the 
accumulation of both NR1 and endogenous CD4 T cells in the infected uterus, but had no 
significant effect on CD4 T cells in the spleen (Figs. 6F, S9A-C). However, while 
continuous MAb treatment in group 2 essentially abrogated NR1 cell trafficking to both 
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steady-state and infected uteri, the number of uterine NR1 cells in group 3 was significantly 
higher than in group 2 and equivalent to that in uninfected uteri of group 1. Ct infection in 
group 1 induced a ~5-fold increase in uterine NR1 cells, whereas late inhibition of α4 
integrins in group 3 completely prevented this secondary boost in uterine NR1 cell numbers. 
There was no difference between groups 1 and 3 in challenge-induced BrdU uptake or Ki-67 
expression (a marker of ongoing cell division) by NR1 cells, indicating that mucosa-resident 
and newly recruited memory cells have a similar proliferative capacity (Fig. S9D). Thus, the 
difference in mucosal T cell numbers between Ct-challenged animals in group 1 and group 3 
likely reflects the α4 integrin dependent influx of circulating TEff that occurred in response 
to infection-induced recruitment signals in the uterus (9). By contrast, the difference 
between groups 2 and 3 provides a measure for the number of vaccine-induced TEff that 
accessed the uterus early after priming and prior to Ct infection. Remarkably, although the 
total number of uterus-resident NR1 cells in group 3 was modest, the bacterial burden was 
reduced by an order of magnitude as compared to naive mice or animals in group 2, which 
remained completely unprotected (Fig. 6G). However, bacterial burdens in group 1 were 
even further reduced than in group 3, indicating that both tissue-resident and circulating T 
cells are needed to achieve optimal clearance of Ct. These findings confirm that the 
migration of both tissue-resident and circulating CD4+ T cells into uterine mucosa depend 
on α4 integrins, presumably the α4β1 heterodimer (56). It is likely that additional trafficking 
molecules, such as chemokines are involved in a tissue-specific multi-step adhesion cascade 
for T cell recruitment to normal uterine mucosa (53), but the molecular identity of these 
constitutive traffic signals remains to be determined.
Circulating memory T cells induced by mucosal vaccination confer partial protection 
against Ct rechallenge
Having documented the protective capacity of mucosal TRM, we next asked whether 
circulating memory cells can be protective in the absence of pre-existing TRM. To this end, 
we performed parabiosis surgery to generate pairs of congenic (CD45.1/CD45.2) mice, 
which establish a shared circulatory system, allowing genetically traceable hematopoietic 
cells from each animal to access the blood and tissues of a conjoined partner (57). Control 
experiments showed that CD4 T cell chimerism (the ratio of partner-derived:endogenous 
cells) in blood was minimal on day 3 post surgery, but approached ~35:65 and 50:50 on 
days 4 and 5, respectively (Fig. S10). Having thus determined that the earliest timepoint for 
circulating T cells to gain access to a parabiotic partner's tissues is on day ~4 after surgery, 
we performed a series of timed parabiosis experiments in congenic pairs of CD90.2+ mice, 
whereby the CD45.1+ animal in each pair was given genetically tagged (CD90.1+) NR1 TN, 
and both mice were immunized with UV-Ct–cSAP on the following day (day 0). Congenic 
pairs were subdivided into six groups: two groups underwent parabiosis surgery on day -14 
or -1 before immunization and four groups were parabiosed on day 1, 4, 14 or 21 after 
immunization (Fig. 7A). Six weeks after vaccination, the number of uterine NR1 TRM was 
similar in all parabionts that had been conjoined on or before day 1 (Fig. 7B). In contrast, 
when parabiosis was initiated on day 4 or thereafter the number of NR1 cells in uteri of non-
immunized CD45.2+ partners of immunized CD45.1+ animals was equivalent to that in 
completely naive parabiotic pairs. These results imply that a transient wave of MALT-
derived TEff gave rise to most if not all uterine TRM within the first 7 days after 
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immunization. Little or no further T cell recruitment to the uterus occurred after this 
timepoint. These findings are in perfect agreement with the timecourse of TEff accumulation 
in uteri of conventional mice, which increased until day 7 and plateaued thereafter (Fig. 6D).
To assess the protective capacity of the circulating memory subset, we devised a 
modification of the above protocol (Fig. 7C), whereby two groups of congenic mice were 
paired and each CD45.2+ partner received 1×105 NR1 TN followed by i.n. UV-Ct–cSAP 
vaccination. Animals in group A were vaccinated 2 weeks after parabiosis, while in group B 
vaccination preceded parabiosis by 2 weeks. After another two weeks, both partners were 
challenged with Ct. Four days later, infected uteri in both vaccinated and naive parabiotic 
animals had recruited substantial numbers of Ct-specific NR1 cells (Figs. 7D, E) that 
exceeded those recovered from unifected uteri of vaccinated mice (Figs. 6D & 7B). Uterine 
NR1 cell recruitment was markedly enhanced in all parabionts in group A, where Ct-specific 
memory cells had been generated after a shared circulation was already established so NR1 
TRM could seed uteri of both partners (Fig. 7D). By contrast, in group B parabiosis was 
performed after the early wave of mucosa-seeding TEff had subsided, so uterus-resident NR1 
TRM were restricted to the immunized CD45.2+ partner (Fig. 7E), whereas circulating 
memory cells could equilibrate between both partners. Consequently, both parabionts in 
group A were effectively protected against genital Ct challenge (Fig. 7F). By contrast, in 
group B only the immunized partners were fully protected, while the bacterial burden in 
non-immunized animals, which harbored only circulating NR1 memory cells were 
indistinguishable from naive NR1 recipients (Fig. 7G). Of note, UV-Ct–cSAP vaccination 
induced a robust humoral response against Ct (Fig. S3A), whereby circulating antibodies are 
expected to fully equilibrate in parabiotic pairs. The preferential protection of only the 
vaccinated parabionts in group B suggests that antibodies provided little or no protection in 
this experimental setting.
While the above experiments permitted simultaneous assessment of the migratory dynamics 
and protective function of Ct-specific T cells, the experimental protocol required that NR1 
TN were transferred at super-physiologic numbers. To control for potential artifacts of 
elevated frequencies of Ct-specific T cells, we performed timed parabiosis experiments 
without NR1 cell transfer. To this end, either the CD45.1+ or CD45.2+ partner of each 
congenic pair was immunized before or after parabiosis surgery and both animals were 
challenged 4 weeks later with Ct i.u. (Fig. 7H). When uterine bacterial burden was assessed 
6 days later, both partners were fully protected when parabiosis had been performed on or 
before day 1 after vaccination (Fig. 7I). Thus, mucosal UV-Ct–cSAP vaccination of animals 
that could generate both TRM and circulating memory cells elicited similar protection 
against Ct challenge with and without prior adoptive transfer of TCR trangenic NR1 cells 
and regardless of whether we examined individual mice (compare Fig. 2A vs. 6G) or 
parabiotic pairs (compare Fig. 7B vs. 7D), indicating that NR-1 cell transfers did not 
artificially skew the overall vaccine response.
Importantly, when parabiosis was delayed until day 4 or later after vaccination, protection of 
the non-immunized parabionts was noticeably compromised. These findings strongly 
support the notion that mucosal seeding by vaccine-induced TRM must occur prior to day 8 
post vaccination (Fig. 7B) and is essential for full-fledged resistance to genital Ct challenge. 
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However, even when parabiosis of animals that did not receive NR1 TN was delayed after 
vaccination until day 4 or later, subsequent Ct challenge of non-immunized partners resulted 
in significantly lower bacterial burdens than when naive parabionts were challenged (Fig. 
7I). Thus, the circulating memory cells that arose from a polyclonal T cell response 
provided meaningful, if partial, protection in the absence of TRM, while the analogous 
experiment after adoptive transfer of NR1 TN failed to reveal protection by circulating 
memory cells (Fig. 7G). This difference was presumably because conventional naive mice 
contain much fewer Ct-specific TN than NR1 cell recipients, allowing the latter to rapidly 
generate a large burst of TEff after Ct challenge that may have masked the activity of 
circulating memory cells. In aggregate, our results suggest that circulating polyclonal 
memory T cells that arise after mucosal vaccination can accelerate uterine Ct clearance, 
even in the absence of mucosal TRM. However, consistent with the partial protection 
afforded by adoptive transfer of sensitized splenic CD4 T cells (Fig. 3B), this protective 
activity is suboptimal.
Mucosal UV-Ct exposure generates suppressive Treg in parabiotic partners
Finally, we examined parabiotic pairs in which the CD45.2+ partner had received i.u. 
conditioning with UV-Ct. Remarkably, both partners displayed similar hypersusceptibility to 
Ct regardless of whether parabiosis was initiated before or after UV-Ct immunization (Figs. 
7J, K), indicating that uterus-resident Treg may not be needed for the tolerogenic response 
to Ct. This is in line with observations in a murine colitis model, where tissue-homing of 
Treg was not required to prevent intestinal inflammation (58).
Mucosal UV-Ct–cSAP vaccination confers protection againstCt challenge in humanized 
mice
The above findings in conventional mice were fully reproducible in two cohorts of BLT 
mice (59) that had been reconstituted with a human immune system from two unrelated 
donors (60). Human CD4 T cells in both cohorts mounted a vigorous mucosal TH1 response 
to clear uterine infection with two different Ct serovars, Ct-L and Ct-E (Figs. 8A, B). 
Moreover, prime-boost vaccination of naive BLT animals with UV-Ct–cSAP given i.n. or 
i.u. (Fig. 8C) was highly effective against subsequent i.u. Ct challenge, even when BLT 
mice were challenged with a different serotype than used for immunization (Fig. 8D, E).
Conclusion
In summary, using a mucosal immunization strategy, we have dissected the multi-facetted 
adaptive immune mechanisms that control murine host responses against genital Ct infection 
after mucosal vaccination with a vaccine candidate, UV-Ct-cSAP. Our results indicate that 
optimal protection after Ct challenge requires uterine recruitment of two discrete waves of 
Ct-specific CD4 T cells that are inducible in MALT, but not in skin-draining LNs (Fig. 8F). 
Following an immunostimulatory mucosal priming event, the first wave is composed of 
recently activated TEff that give rise to long-lived TRM after trafficking to both inflamed and 
resting mucosal surfaces. This early migratory wave subsides within ~one week after 
immunization and depends on a constitutive tissue-specific multi-step adhesion cascade (53) 
involving α4 integrins and presumably other mucosal traffic signals that remain to be 
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identified. Concomitantly, MALT-derived Ct-responsive TEff also generate a second 
population of memory cells that preferentially reside in blood and secondary lymphoid 
organs. This systemic memory population, which is comprised of the two classical central 
and effector memory subsets (61), does not appear to access the resting urogenital mucosa, 
but can be recruited to peripheral tissues, including uterine mucosa, upon the onset of 
inflammation (62). Although this circulating memory subset contributes to the overall recall 
response against Ct, its protective role is suboptimal in the absence of TRM. In an optimally 
immunized individual, Ct infection triggers rapid release of cytokines, particularly IFN-γ, by 
the mucosal TRM subset, which promotes pathogen clearance (63). This protective effect of 
uterine TRM may be amplified by their pro-inflammatory activity that may help recruit 
circulating memory cells, however, our data show that the tissue-resident memory subset 
confers substantial protection even when the influx of circulating memory cells is blocked.
Of importance to future Ct vaccine trials, our experiments potentially shed light on the 
decades-old conundrum of how exposure to killed Ct in trachoma vaccine trials during the 
1960s may have enhanced subsequent Ct-induced pathology (25-29). We could provoke a 
similar hypersusceptibility to Ct in our mouse model by exposing mucosal surfaces to UV-
Ct, an effect that was due to de novo induction of Ct-specific Treg. After conjugating cSAPs 
to UV-Ct for mucosal immunization, we could not only prevent this tolerogenic effect, but 
also render mice highly resistant to Ct infection, a protective response that was identical in 
magnitude, longevity and immunological mechanism to the endogenous memory response 
against genuine Ct infection. Moreover our findings in BLT mice indicate that human CD4 
T cells can also mount a vigorous mucosal TH1 response to clear uterine Ct infection, 
suggesting that cSAP-based mucosal vaccination may also elicit protective immune 
responses in humans. As cSAPs are fully synthetic and biodegradable nanoparticles that are 
easily manufactured and well tolerated, they may also offer a powerful and versatile 
approach for mucosal vaccine development against other challenging pathogens.
Materials and Methods
Mice
C57BL/6 and BALB/c mice, 6-8 weeks old, were purchased from Charles River or The 
Jackson Laboratory. B6.129S2-H2dlAb1-Ea/J (referred to as MHC class II−/−) (48), CD8−/−, 
μMt, Il10−/−, Rag2−/− and C57BL6 B6.SJL Ptprca Pep3b/BoyJ (CD45.1+) mice were were 
purchased from The Jackson Laboratory and used at 6–12 weeks of age. CD90.1 NR1 mice 
(TCR tg mice with specificity for the CD4+ T cell antigen Cta1 from Ct) were bred in-house. 
For some experiments, we crossed NR1 and Foxp3eGFP mice (64). For characterization of 
uterine APC subsets CXCR3GFP/+ mice (65) were used. BLT mice were generated in the 
MGH Humanized Mouse Program by transplanting irradiated NOD/SCID/γc–/– mice with 
human fetal liver stem cells and autologous thymic grafts (59). Reconstituted mice 
developed a fully human lymphoid compartment within ~13-18 weeks post reconstitution at 
which stage they were used for immunization or vaccination studies. All experiments were 
performed in accordance with NIH guidelines and approved by the Institutional Animal 
Committees of Harvard Medical School and MGH.
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Chlamydia infection and detection
Ct serovar L2 (434/Bu), referred to as Ct, or servar E (Ct-E) or C. muridarum (Cm) were 
propagated in McCoy cell monolayers grown in Eagle's MEM (Invitrogen, Grand Island, 
NY) supplemented with 10% FCS, 1.5 g/l sodium bicarbonate, 0.1 M nonessential amino 
acids, and 1 mM sodium pyruvate, as described previously (41). Aliquots were stored at 
−80°C in medium containing 250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-
glutamic acid and were thawed immediately prior to use. All mice were treated with 2.5 μg 
medroxyprogesterone s.c. 7 days prior to immunization to normalize the murine estrous 
cycle. For UV inactivation, Ct or Cm suspensions were placed under a UV lamp (15 W) at a 
distance of 30 cm for 30 min. The efficiency of UV inactivation was always tested by 
infecting McCoy cell monolayers with an aliquot of UV-inactivated Ct and evaluation of 
inclusion-forming units. Briefly, 30 hours following infection the media was removed, cells 
were fixed in ice-cold methanol and permeabilized in PBS with .05% tween. Cells were then 
stained with 10 μl anti-MOMP antibody and Evans blue counterstain (Pathfinder Diagnostic 
Kit BioRad) for one hour and were then washed 3 times in PBS-tween. Inclusion-forming 
units were not observed after UV inactivation of Ct or Cm.
Intrauterine immunization and challenge were conducted transcervically using an NSET 
device (ParaTechs) as previously described (31). Briefly, 10μ l of sucrose-phosphate-
glutamate media containing 106 Ct or UV-Ct +/− cSAP was placed into the uterus using the 
NSET pipet tip through the NSET speculum. Subcutaneous immunization was done with a 
U-100 insulin syringe injecting 10μl of sucrose-phosphate-glutamate media containing 106 
Ct or UV-Ct +/− cSAP. As 106 Ct were lethal for mice when deposited intranasally (data not 
shown), i.n. immunization was performed with 105 Ct in 10μl of sucrose-phosphate-
glutamate media. Cm was administered intravaginally as described previously (6).
To quantify the levels of Ct in tissues, we usually used qPCR with 16S primers specific for 
Ct, as described previously (66). Briefly, DNA was isolated from uterus homogenates using 
the QIAamp DNA mini kit (Qiagen). Mouse GAPDH DNA and Chlamydia 16S DNA were 
quantified by qPCR on an ABI Prism 7000 sequence detection system. Using standard 
curves from known amounts of Ct and mouse DNA, the amount of Chlamydia DNA (in pg) 
per unit weight of mouse DNA (in μg) was calculated to assess bacterial burden.
Titers of inclusion-forming units were determined in two experiments. Mouse uteri were 
disrupted using a tissue homogenizer and frozen at −80C. Aliquots were thawed and tenfold 
dilutions of each sample were made in a 96 well plate. Each dilution was then used to infect 
a confluent monolayer of McCoy cells in a 96 well plate by centrifugation for 1 hour at 37C. 
Two hours following centrifugation media was supplemented with 25ug/ml of gentamicin to 
prevent contamination. 30 hours following infection the media was removed, cells were 
fixed in ice cold methanol and permeabilized in PBS with .05% tween. Cells were then 
stained with 10ul anti-MOMP antibody and evans blue counterstain (Pathfinder Diagnostic 
Kit BioRad) for one hour then were washed 3 times in PBS-tween. Total inclusions in each 
sample were then enumerated by fluorescence microscopy with at least 3 fields being 
counted per sample.
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The impact the cSAP constructs on chlamydia-induced pathology of the upper genital tract 
was measured 4 weeks after Cm challenge of immunized mice and naïve controls. Gross 
pathology was scored by hydrosalpinx development as follows: 0: normal; 1: low-level fluid 
in oviduct; 2: moderate amount of fluid present; 3: high level of fluid.
Vaccine formulation
Synthesis of polymers and formulation of synthetic nanoparticles (SPs) was performed as 
described previously (32) with minor modifications. Briefly, the triblock copolymer 
poly(d,l-lactic-co-glycolic acid)-b-poly(l-histidine)-b-poly(ethylene glycol) (PLGA-PLH-
PEG, referred to as charge-switching synthetic particles, cSPs) was synthesized using a 
polymer end grafting strategy. Control SPs that lacked the PLH block were formulated in a 
similar manner using PLGA-PEG copolymers. R848-PLA was synthesized by ring opening 
polymerization (33). All SPs were formulated using a modified emulsion/solvent 
evaporation technique. R848-PLA was added in a 0.4:0.4:0.2 (R848-PLA:PLGA-PLH-
PEG:PLGA-PEG) ratio. The polymer-containing ethyl acetate solution was sonicated into 2 
mL of pure water using a probe tip sonicator (Misonix Sonicator S-4000, Farmingdale, NY) 
for 30 sec in continuous mode at 40% amplitude then diluted into 8 mL of pure water under 
magnetic stirring in a fume hood. The solvent was allowed to evaporate for at least 2 hours, 
at which point SPs were collected and purified by repeated ultrafiltration using Amicon 
Ultra-4 100,000 NMWL cutoff filters (Millipore, Billerica, MA). The sizes of Ct-SP 
constructs were determined by dynamic light scattering on a Zetasizer Nano (Malvern 
Instruments).
SAPs, cSAPs and cSPs were prepared, purified, then resuspended in a dilute pH 6.0 solution 
and 2×107 UV-Ct were added per mg SPs. This mixture was then incubated at 37°C for at 
least 30 minutes in the dark under gentle shaking. To determine SP conjugation to the 
surface of UV-Ct, Ct was labeled with BacLight (Life Technologies, (absorption maximum 
581, emission maximum 644) and PLGA-AF488, synthesized using ring-opening 
polymerization, was blended in to the SPs prior to conjugation with bacteria and analyzed 
with flow cytometry.
Tissue digestion, flow cytometry and cell sorting
Spleens, lungs, lymph nodes, and livers were cut into small pieces with a sterile scalpel and 
passed through 40μm mesh filters. Uteri were digested with type XI collagenase (Sigma, St 
Louis, MO) and DNase I (Sigma) for 30 min at 37°C before passing through 40μm filters. 
Samples were enriched for lymphocytes by density-gradient centrifugation with NycoPrep™ 
1.077 according to the manufacturer's protocol (Axis-Shield).
For flow cytometry analysis or cell sorting, T cells were stained with anti-CD3e (145-2C11; 
BioLegend), anti-CD4 (RM4-5; BioLegend), anti-CD90.1 (OX-7; BioLegend), anti-CD25 
(PC61; BioLegend), anti-Va2 (B20.1; BioLegend), anti-Vb8.3 (1B3.3; BD Biosciences), 
anti-CD45.1 (104; BioLegend), or anti-CD45.2 (A20; BioLegend). T cell proliferation was 
measured by anti-Ki-67 (16A8; BioLegend) staining and overnight Bromodeoxyuridine 
(BrdU) labeling according to the manufacturer's protocol (Life Technologies). DCs were 
characterized and/or sorted with anti-MHC class II (AF6-120.1; BioLegend), anti-F4/80 
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(BM8; BioLegend), anti-CD103 (2E7; BioLegend), anti-CD11c (N418; BioLegend), anti-
CD11b (M1/70; BioLegend), anti-CD207 (eBioL31; eBioscience), anti-CD301b (URA-1; 
BioLegend), anti-CD80 (16-10A1; BioLegend), anti-CD86 (GL-1; BioLegend), anti-CD274 
(PD-L1) (10F.9G2; BioLegend), anti-CD273 (PD-L2) (TY25; BioLegend), anti-IL-10 
(JES5-16E3; BioLegend), and anti-IL-12/IL-23 (C15.6; BioLegend). For intracellular T cell 
cytokine staining, autologous sorted splenic CD11c+ DCs were pulsed with UV-inactivated 
EBs for 30 min, washed extensively and added to T cells for 5 h in the presence of brefeldin 
A (GolgiStop; BD Biosciences). T cells were stained for anti–IFN-γ (XMG1.2; BioLegend) 
anti–IL-2 (JES6-5H4; BioLegend), and anti–TNF-α (MP6-XT22; BioLegend) Abs after 
permeabilization with the Cytofix/Cytoperm Plus Kit according to the manufacturer's 
instructions (BD Biosciences). The absolute cell number in each sample was determined 
using AccuCheck Counting Beads (Invitrogen). Data were collected on a FACSCanto (BD 
Biosciences) or a LSRII (BD Biosciences) and analyzed using FlowJo 9.3.2. A FACSAria 
(BD) was used for cell sorting with Diva software and purity was >98% for all experiments.
Adoptive transfer of leukocyte subsets
Lymph nodes and spleens were collected from naive female CD90.1+ NR1 mice and 
purified by negative immunomagnetic cell sorting using a mouse CD4+ T-cell isolation kit 
(~98% CD4+, Miltenyi Biotec). Purity was verified with anti-CD4, anti-Va2 and anti-Vb8.3 
stainings. For some experiments, FoxP3eGFP+ NR1 cells were depleted before adoptive 
transfer of FoxP3eGFP− NR1 cells by cell sorting. 1×105 isolated NR1 cells (unless noted 
elsewise) were intravenously transferred to naïve recipient mice 1 day prior immunization. 
In proliferation experiments, NR1 cells were labeled with carboxyfluorescein succinimidyl 
ester (CFSE) before transfer. For adoptive transfer of polyclonal CD4+ and CD8+ T cells 
and T cell-depleted leukocytes, cell subsets from immunized mice were harvested from 
donor spleens by immunomagnetic cell sorting (Miltenyi Biotec ) and 107 cells were 
transferred to naïve recipients.
NR1 T cell stimulation by APCs
APCs were isolated from single-cell suspensions of uterus and draining LNs 18 and 24 
hours post-immunization, respectively. CD45+MHC class II+ cells were FACS sorted based 
on their CD103 and F4/80 expression (CD103−F4/80+ macrophages, CD103−F4/80− DCs 
and CD103+F4/80− DCs). Sorted cells were either subjected to qPCR analysis for Ct 16S 
content or co-cultured with CFSE-labeled NR1 cells for 3 days (500 DCs and 5,000 NR-1 
cells). For in vivo assessment of APC function, naïve mice received 1×105 CFSE-labeled 
NR1 cells i.v. followed one day later by s.c. injection into the right footpad of 5,000 sorted 
APCs. CFSE-dilution of NR1 cells in the right popliteal LN was analyzed 3 days later.
In vivo MAb treatment
250μg anti-CD25 (PC61) mAb or control IgG were administrated intraperitoneally at days 
−3 and +3 of uterine Ct challenge. Anti-a4 mAb (PS/2) or control IgG was administrated i.v. 
at day 3 (100μg) and every second day (50μg) until day 11 thereafter. On d9 mice were 
challenged i.u. with 106 IFU of Ct.
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Parabiosis
Parabiosis surgery was performed as previously described (57). Briefly, sex- and weight-
matched congenic partners were anaesthetized with ketamine (100 mg/kg body weight) and 
xylazine (10 mg/kg body weight) by i.p. injection. The corresponding lateral aspects of mice 
were shaved and the excess hair was wiped off with alcohol prep pad. Two matching skin 
incisions were made from the olecranon to the knee joint of each mouse, and the 
subcutaneous fascia was bluntly dissected to create about 0.5 cm of free skin. The olecranon 
and knee joints were attached by a double 4-0 braided silk suture and tied, and the dorsal 
and ventral skins were approximated by staples or continuous 6-0 braided silk suture. The 
mice were then kept on heating pads and continuously monitored until recovery. 2.5μg g−1 
flunixin was used for analgesic treatment by subcutaneous injection every 12h for 48h after 
the operation. After 3 days to 2 weeks, chimerism of leukocytes from the blood was 
analyzed monitored to ensure equivalent blood exchange between parabiotic partners. 
Depending on the readout of the experiments, either one of the partners was immunized with 
UV-Ct–cSAP i.n. or UV-Ct i.u. and both were challenged with Ct i.u., or 105 NR1 cells 
were i.v. injected the day before immunization with UV-Ct–cSAP i.n. without further 
challenge.
Anti-Ct Ab ELISA
Antibody levels were determined by enzyme-linked immunosorbent assays (ELISA) using a 
mouse Ct antibody ELISA Kit (MyBioSource). Mice were bled 4 weeks after immunization 
in order to assess antibody levels.
Confocal and electron microscopy
Uterine tissue was incubated overnight in phosphate-buffered L-lysine with 1% 
paraformaldehyde/periodate and then cryoprotected by subsequent incubations in 10%, 20%, 
and 30% sucrose in PBS at room temperature, snap-frozen in TBS tissue-freezing liquid 
(Triangle Biomedical Sciences) and stored at −80°C. Sections of 30μm thickness were 
mounted on Superfrost Plus slides (Fisherbrand) and stained with anti-CD90.1 PE (OX-7, 
BD Biosciences), anti-CD326 FITC (G8.8: BioLegend) and anti-CD31 (390, BioLegend) in 
a humidified chamber after Fc receptor blockade with 1 mg/ml−1 antibody 2.4G2 (BD 
Pharmingen). Samples were mounted in FluorSave reagent solution (EMD-Calbiochem) and 
stored at 4°C until analysis. Images were acquired with an Olympus Fluoview BX50WI 
inverted microscope and were analyzed by using Volocity software (Improvision).
Transmission electron microscopy (TEM) samples were prepared using the Gatan Cryo-
Plunge3 and imaged using a JEOL 2100 FEG electron microscope.
Statistical analysis
Statistical significance was determined between two groups with two-tailed t-test. Statistical 
differences among three or more groups were assessed using one-way or two-way analysis 
of variance followed by Bonferroni's post-test to account for multiple comparisons. 
Significance was set at a P value of less than 0.05.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Differential effects of immunization with Ct / UV-Ct and conjugation of UV-Ct with 
synthetic nanoparticles
(A) Schematic diagram of the immunization and challenge protocol for Figs. 1B-C, 2A-C, 
2F, 3A-B, 4E-F, 6A, S4 and S7. Mice were immunized with Ct, UV-Ct, UV-Ct-cSAP or 
UV-Ct mixed with control nanoparticles (Ct, live Chlamydia trachomatis; UV-Ct, 
inactivated Chlamydia trachomatis; UV-Ct-cSAP, inactivated Chlamydia trachomatis 
complexed with charge-switching synthetic adjuvant particles; UV-Ct + SAP, inactivated 
Chlamydia trachomatis mixed with synthetic adjuvant particles (not attached to UV-Ct); 
UV-Ct-cSP inactivated Chlamydia trachomatis complexed with charge-switching synthetic 
particles (without adjuvant)) via intrauterine (i.u.), intranasal (i.n.) or subcutaneous (s.c.) 
routes. Challenge with live Ct was always i.u. (B) Uterine Ct burden was measured by qPCR 
6 days post i.u. challenge with live Ct in naïve mice and in animals that had been immunized 
4 weeks earlier by i.u. injection of infectious Ct or UV-Ct. Data are pooled from 4 
independent experiments (n= 20 mice per group; **P<0.01; ***P<0.001; one-way ANOVA 
followed by Bonferroni's post-test). (C) Ct burden following i.u. or s.c. immunization with 
UV-Ct mixed with adjuvants: alum, aluminum hydroxide; IMQ, imiquimod; CpG, CpG 
oligodeoxynucleotide type C (n= 5-7 mice per group; **P<0.002; ***P<0.001; one-way 
ANOVA followed by Bonferroni's post-test). (D) Schematic representation of surface 
charge-switching synthetic adjuvant particle (cSAP) production and conjugation to UV-Ct. 
(E-F) UV-Ct stained with BacLight was incubated with Alexa Fluor488 labeled cSAP or 
SAP at pH 7.4 or 6.0. (E) Representative FACS plots and (F) quantification of nanoparticle 
conjugates with UV-Ct from 2 independent experiments. ***P<0.001; ns, not significant; 
two-tailed t-tests. (G) A representative cryo-transmission electron micrograph of a UV-Ct–
cSAP cluster showing cSAP in red and UV-Ct in blue. Scale bar: 100 nm. (H) Dynamic 
light scattering profiles of UV-Ct–cSAP, cSAP and UV-Ct alone. The population 
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distribution is representative of the volume scattering intensity. Data are representative of 10 
independent experiments. Error bars represent mean ± SEM.
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Figure 2. Intrauterine immunization with UV-Ct–cSAP protects against challenge with live Ct
(A) Ct burden following i.u. challenge with live Ct 4 weeks after immunization (n=4-10 
mice/group; **P<0.01; ***P<0.001). (B-C) Timecourse of Ct burden following i.u. Ct 
challenge 4 weeks after immunization (n=4 mice/group/timepoint, ***P<0.001) measured 
by (B) qPCR or (C) in vitro assessment of inclusion-forming units (IFUs). (D) Ct burden 
following intravaginal challenge with Cm 4 weeks after immunization with Cm and UV-Cm-
cSAP. n = 3-4 mice/group; *** P<0.001. (E) Gross uterine pathology determined as 
hydrosalpinx score 4 weeks after intravaginal challenge of immunized and naïve mice with 
Cm (n=8 mice/group; **P<0.01, ***P<0.001. (F) Ct burden following i.u. Ct challenge 6 
months after i.u. im munization (n=4-10 mice/group; ***P<0.001). Statistical differences 
were assessed using one-way ANOVA followed by Bonferroni's post-test.
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Figure 3. Intrauterine immunization with UV-Ct or UV-Ct–cSAP leads to differential activation 
of Ct-specific CD4+ T cells
(A) Ct burden following i.u. Ct challenge of MHC-II−/−, CD8−/− or μMt mice 4 weeks after 
immunization (n=2-11 mice/group; ***P<0.001). (B) Ct burden in i.u. infected mice that 
received adoptive transfers of leukocyte subsets from naive or immunized donors. Pooled 
data from 2 independent experiments (n=4-7 mice/group; ***P<0.001). (C-F) Flow 
cytometric analysis of Ct-specific NR1 cells in uterus and draining iliac LNs 4 days after i.u. 
immunization. (C) NR1 cell proliferation in uterus draining LNs. Representative histograms 
show CFSE dilution, a measure of T cell proliferation, in one of three independent 
experiments. (D-E) Absolute number of NR1 cells recovered from (D) iliac LNs and (E) the 
uterus. (F) Intracellular cytokine staining for TNF-α, IFN-γ, and IL-2 in iliac LN-derived 
NR1 cells after ex vivo restimulation with Ag-pulsed DCs. Data are shown as percentage of 
total NR1 cells expressing each combination of cytokines (n=5 mice/group; *P<0.05). 
Statistical differences were assessed using one-way ANOVA followed by Bonferroni's post-
test.
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Figure 4. UV-Ct-induced tolerance is mediated by FoxP3+ NR-1 cells
(A-D) Sorted GFP− NR1xFoxP3-eGFP TN were adoptively transferred to naïve mice prior 
to immunization. Total GFP+CD25+ NR1 cells (CD4+Vβ8.3+Vα2+) were enumerated by 
FACS in single-cell suspensions of (A, B) iliac LNs and (C, D) uterus 4 days after 
immunization and are shown as (A, C) representative contour plots of NR1 cells and (B, D) 
percent of total NR1 cells (n=5 mice/group; **P<0.01). (E) Ct burden following i.u. Ct 
challenge 4 weeks after immunization with Ct, UV-Ct or UV-Ct–cSAP. In some animals 
Treg were depleted with anti-CD25 mAb (clone PC61), while the other groups received 
isotype-matched IgG three days before and after challenge (n=6 mice/group; ***P<0.001). 
(F) Ct burden following i.u. challenge with live Ct 4 weeks after immunization of Il10−/− 
mice. (n=5-11 mice/group; *P<0.05; **P<0.01; ***P<0.001). Error bars depict mean ± 
SEM. Statistical differences were assessed using one-way ANOVA followed by 
Bonferroni's post-test.
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Figure 5. Distinct uterine DC subsets acquire Ags after i.u. Ct and UV-Ct-cSAP versus UV-Ct 
immunization and induce differential responses by Ct-specific T cells in vitro and in vivo
(A) Schematic diagram of the experimental protocol for panels B-F. Mice were immunized 
i.u. with Ct, UV-Ct, or UV-Ct–cSAP. At indicated timepoints thereafter, CD45+MHC-II+ 
APC subsets were isolated from uteri and LNs and FACS sorted based on CD103 and F4/80 
expression. Uptake of Ct per 1,000 sorted APCs in the uterus (B) and draining LN (C) was 
measured by qPCR. Isolated uterine CD326+ epithelial cells (EC) served as positive control 
for uterine samples. Data are pooled from two independent experiments. Mac, macrophages; 
DC, dendritic cells. n=2-7; broken line, limit of detection; *P<0.05; **P<0.01; ***P<0.001. 
(D) In vitro proliferation of NR1 TN was determined by CFSE dilution after incubation with 
sorted APC subsets for 3 days (n=4 mice/group; *P<0.05). (E) In vivo proliferation of 
CFSE-labeled CD90.1+ NR1 cells in a draining popliteal LN 3 days after footpad injection 
of APC subsets (n=4 mice/group; *P<0.05). (F) FoxP3-eGFP-depleted NR1 cells were 
incubated in vitro with sorted APC subsets. Frequencies of FoxP3-eGFP+ Treg were 
determined by flow cytometry after 3 days (n=4 mice/group; *P<0.05). (G) 18 hours after 
immunization uterine DC subsets were analyzed by FACS for indicated markers (n=4). 
Error bars represent mean ± SEM. Statistical differences were assessed using one-way 
ANOVA followed by Bonferroni's post-test.
Stary et al. Page 27
Science. Author manuscript; available in PMC 2015 December 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. Generation and protective function of uterus-resident and systemic memory T cell 
subsets induced by intranasal UV-Ct–cSAP vaccination
(A) Ct burden was determined by qPCR following i.u. Ct challenge 4 weeks after s.c. or i.n. 
immunization (n=5-8 mice/group). (B) Timecourse of circulating NR1 TEff during days 1-11 
post immunization (n=4 mice/group). (C) Total number of NR1 cells recovered from 
indicated tissues on days 7 and 30 following i.n., s.c. or i.u. immunization. LN, mesenteric 
lymph node. (D) Timecourse of uterine NR1 cell accumulation during days 1-11 post 
immunization (n=4 mice/group). (E) Schematic protocol for timed neutralization of α4 
integrins in the 3 groups of UV-Ct-cSAP vaccinated mice shown in panels F-G. (F) Total 
number of uterus-resident NR1 cells determined by flow cytometry (n=4 mice/group). (G) 
Uterine Ct burden 3 days after i.u. Ct challenge. Data are from 2 independent experiments; 
n=4-8 mice/group. Statistical differences were assessed using one-way ANOVA followed by 
Bonferroni's post-test.
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Figure 7. Mucosal UV-Ct–cSAP vaccination rapidly induces a transient wave of TEff that 
generate protective TRM in uterine mucosa
(A) Schematic protocol for timed parabiosis experiments in panel B. Parabiosis of 
CD90.2+CD45.2+ mice with CD90.2+CD45.1 partners was performed on indicated days 
before or after i.n. immunization of both partners with UV-Ct–cSAP. (B) On day −1, the 
CD45.1 animal received 1×105 CD90.1+ NR1 TN and uterine NR1 TRM were counted 6 
weeks later (n=2-4 UV-Ct-cSAP immunized pairs and 2 naïve parabiotic pairs). (C) 
Schematic protocol for parabiosis experiments in panels D-G and J-K. CD90.2+CD45.2+ 
mice were immunized with UV-Ct–cSAP i.n. or UV-Ct i.u. 2 weeks before or after 
parabiosis with a CD90.2+CD45.1 partner. 1×105 CD90.1+ NR-1 TN were adoptively 
transferred to the CD45.2+ animal one day prior to immunization. Animals were either 
immunized 2 weeks after (group A; panels D, F, J) or two weeks before parabiosis surgery 
(group B; panels E, G, K). n = 3 parabiotic pairs immunized with UV-Ct-cSAP or UV-Ct 
and 2 naive parabiotic pairs. (D, E) Total number of NR1 cells in the uterus 4 days after Ct 
challenge (n = 3 parabiotic pairs immunized with UV-Ct-cSAP and 2 naïve parabiotic pairs. 
**P<0.01). (F-G) Ct burden 4 days after i.u. Ct challenge of both partners in animals that 
had been conditioned with i.n. UV-Ct-cSAP. (H) Schematic protocol for timed parabiosis 
experiments in panel I. One partner of each CD45.1/CD45.2 congenic pair was randomly 
chosen to be immunized on day 0 and underwent parabiosis surgery at indicated timepoints. 
(I) Both parabionts in each pair (n=3-4/group) were challenged i.u. with Ct on day 28. Non-
immunized parabiotic pairs served as naive controls (n=4). Ct burden was assessed 6 days 
after challenge. All groups were significantly different from naïve parabionts (P<0.05; one-
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way ANOVA followed by Bonferroni's post-test.). (J, K) Uterine Ct burden 4 days after 
both i.u. Ct challenge of parabiotic partners after conditioning with i.n. UV-Ct. ***P<0.001; 
ns, non significant. Error bars show mean ± s.e.m. Unless stated otherwise, statistical 
differences were assessed using two-tailed t-test.
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Figure 8. Humanized BLT mice are protected from Ct challenge after UV-Ct-cSAP 
immunization
(A, B) Immune response of a cohort of humanized BLT mice to uterine infection with Ct-E 
or Ct-L. All animals had been reconstituted with human fetal thymus, liver and 
hematopoietic stem cells from the same donor. (A) Number of IFN-γ producing human CD4 
T cells per uterus (n = 5 mice/timepoint; *P<0.05). (B) Animals were infected on day 0 and 
rechallenged on day 21 (arrows). Uterine Ct burden was measured on days 4, 14, 21 or 25 
by qPCR. LOD, limit of detection; Ct-E, C. trachomatis serotype E; Ct-L, C. trachomatis 
serotype L. n = 2 mice/group. *P<0.05. (C) Schematic protocol for experiments in panels D 
and E. These experiments were performed using two cohorts of BLT mice that had been 
reconstituted with material from different human donors. (D-E) BLT mice were left naive or 
immunized (day 0) and boosted (day 14) as indicated using Ct serotype E (Ct-E) as 
immunogen. All animals were challenged with live Ct-E or Ct serotype L (Ct-L) on day 28. 
Ct burden was determined (D) by qPCR or (E) by measurement of IFUs on day 6 after 
challenge (n=1-9 mice/group pooled from 2 independent experiments with material from 
genetically different human donors). *P<0.05; **P<0.01; ***P<0.001; ns, not significant. 
Error bars reflect mean ± SEM. (F) Schematic summary conclusion. Two waves of vaccine-
induced Ct specific memory T cells must access the uterine mucosa to confer optimal 
protection against Ct challenge. Mucosal vaccination against Ct induces an early burst of 
circulating TEff (solid lines) that seed the uterine mucosa during the first week after 
immunization (wave 1) and give rise to long-lived resident memory T cells. By contrast, 
non-mucosal vaccines do not induce this first wave of mucosa-tropic memory cells (broken 
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lines). Regardless of vaccination route, immunized hosts generate circulatory memory T 
cells, which do not traffic to resting uterine mucosa and are slow to access the re-challenged 
uterus in the absence of pre-existing TRM. However, in mucosal vaccine recipients uterine 
TRM can respond instantly to rechallenge with Ct and instigate the rapid recruitment of 
additional Ct-specific memory cells from the circulating pool (wave 2). Our results indicate 
that memory cells from both waves are required for optimal clearance of uterine Ct 
infection. Statistical differences were assessed using one-way ANOVA followed by 
Bonferroni's post-test.
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